Suven Life Sciences rises 3% on product patents in India and South Korea

Suven announced that the grant of one product patent from India and one product patent from South Korea corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

Suven Life Sciences shares gained as much as 3 percent in morning Tuesday on securing product patents in India and South Korea.

stock premium tips
"....announces that the grant of one product patent from India and one product patent from South Korea corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases," the pharma company said in its filing

These patents are valid through 2029 and 2033 respectively, it added.

The granted claims of the patents include the class of selective Alpha4 Beta2 and 5-HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, narcolepsy, Parkinson and schizophrenia respectively, it said.


At 10:46 hrs Suven Life Sciences was quoting at Rs 194.90, up Rs 3.70, or 1.94 percent.


Two days Free Trials and best services packages for dealing in Stock market click here to get >> stock premium tips One Missed call on @9644405056

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

सकारात्मक वैश्विक रुझानों के सहारे बाजार में मजबूती, निफ्टी 10,900 के ऊपर

11-year data suggests bears control D-Street in September; can bulls defy odds?